Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis

被引:82
作者
Czekalla, J
Beasley, CM
Dellva, MA
Berg, PH
Grundy, S
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Lilly Deutschland, CNS, Div Med, Bad Homburg, Germany
关键词
D O I
10.4088/JCP.v62n0310
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: There may be a temporal association between some antipsychotics and prolongation of the heart-rate-corrected QT interval (QTc) representing a delay in ventricular repolarization. QTc prolongation significantly exceeding normal intraindividual and interindividual variation may increase the risk of ventricular tachydysrhythmias, especially torsade de pointes, and therefore, sudden cardiac death. Method: Electrocardiogram recordings obtained as part of the safety assessment of olanzapine in 4 controlled, randomized clinical trials (N = 2700) were analyzed. These analyses were conducted to characterize any change in QTc temporally associated with olanzapine, compared with placebo, haloperidol, and risperidone, in acutely psychotic patients (DSM-III-R and DSM-IV) and to characterize variability and temporal course of the QTc in this patient population. Changes from baseline to minimum and maximum QTc were tested for significance, and baseline to acute-phase endpoint change in mean QTc was tested for significance within treatments and for differences between olanzapine and comparators. The possibility of a linear relationship between dose of olanzapine and mean change in QTc, as well as incidence of treatment-emergent prolongation of QTc (change from < 430 msec at baseline to <greater than or equal to> 430 msec at endpoint), was tested. Results: The incidence of maximum QTc greater than or equal to 450 msec during treatment was approximately equal to the incidence of QTc greater than or equal to 450 msec at baseline. Conclusion: Results of these analyses suggest that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute to QTc prolongation resulting in potentially fatal ventricular arrhythmias.
引用
收藏
页码:191 / 198
页数:10
相关论文
共 53 条
  • [1] Bazett HC, 1920, HEART-J STUD CIRC, V7, P353
  • [2] Beasley CM, 1997, J CLIN PSYCHIAT, V58, P13
  • [3] Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
    Beasley, CM
    Sanger, T
    Satterlee, W
    Tollefson, G
    Tran, P
    Hamilton, S
    Green, A
    Dott, S
    Pfister, G
    Roxas, L
    Small, J
    Thomas, M
    Ames, D
    Schooler, N
    Baker, R
    Levine, R
    Fabre, L
    Friedel, R
    Safferman, A
    Lieberman, J
    Stahl, S
    [J]. PSYCHOPHARMACOLOGY, 1996, 124 (1-2) : 159 - 167
  • [4] Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial
    Beasley, CM
    Tollefson, G
    Tran, P
    Satterlee, W
    Sanger, T
    Hamilton, S
    Fabre, L
    Small, J
    Ereshefsky, L
    True, J
    Nemeroff, C
    Risch, SC
    Perry, PJ
    Potkin, SG
    Borison, RL
    James, S
    Meltzer, HY
    Iqbal, N
    Fann, WE
    Gewirtz, GR
    Landbloom, R
    RoyByrne, PP
    Tuason, VB
    Carman, JS
    Stokes, PE
    Williams, R
    Ancill, RJ
    MacEwan, GW
    Gujavarty, KS
    Jones, B
    Lohr, JB
    [J]. NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) : 111 - 123
  • [5] Monitoring of olanzapine in serum by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry
    Bogusz, MJ
    Krüger, KD
    Maier, RD
    Erkwoh, R
    Tuchtenhagen, F
    [J]. JOURNAL OF CHROMATOGRAPHY B, 1999, 732 (02): : 257 - 269
  • [6] Olanzapine pediatric overdose
    Bond, GR
    Thompson, JD
    [J]. ANNALS OF EMERGENCY MEDICINE, 1999, 34 (02) : 292 - 293
  • [7] Bonin MM, 1999, PEDIATR EMERG CARE, V15, P266
  • [8] Intoxication with olanzapine
    Bosch, RF
    Baumbach, A
    Bitzer, M
    Erley, CM
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (02) : 304 - 305
  • [9] CARDIOTOXICITY MORE COMMON IN THIORIDAZINE OVERDOSE THAN WITH OTHER NEUROLEPTICS
    BUCKLEY, NA
    WHYTE, IM
    DAWSON, AH
    [J]. JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1995, 33 (03): : 199 - 204
  • [10] Overdose profiles of new antipsychotic agents
    Capel, MM
    Colbridge, MG
    Henry, JA
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2000, 3 (01) : 51 - 54